Seattle

GREATERGOOD.ORG ANNOUNCES WINNER OF GIRLS’ VOICES AT HOME “CLASS OF 2020” CHALLENGE THAT INSPIRES STUDENTS TO SHARE VIDEOS ON HOW THE CORONAVIRUS CHANGED THEIR SENIOR YEAR

Friday, May 29, 2020 - 5:20pm

The Class of 2020 Challenge provided 379 students worldwide in 49 countries the opportunity to share how the coronavirus pandemic has changed their senior year.

Key Points: 
  • The Class of 2020 Challenge provided 379 students worldwide in 49 countries the opportunity to share how the coronavirus pandemic has changed their senior year.
  • Thank you so much for this opportunity and for providing such a platform for all girls to share their stories," said April Judd.
  • For many college and high-school seniors in the graduating class of 2020, the coronavirus pandemic has dramatically changed their final year, said Patricia Cogley, Director of Girls Voices.
  • The Class of 2020 Challenge is an initiative of Girls Voices at Home.

SEngine Precision Medicine Presented Data at ASCO 2020 on Clinical Validation of the CLIA Certified PARIS® Test, a Revolutionary Organoid Based Assay, to Personalize Cancer Treatments

Friday, May 29, 2020 - 2:00pm

The PARIS Test provides valuable drug sensitivity data not yet explained by the current translation of DNA sequencing results.

Key Points: 
  • The PARIS Test provides valuable drug sensitivity data not yet explained by the current translation of DNA sequencing results.
  • Retrospective concordance between clinical outcomes of prior treatments and organoid drug sensitivity data demonstrated PARIS Test accuracy.
  • Details related to the poster presentation are as follows:
    Title: Predictive value of a CLIA-approved organoid based drug sensitivity test.
  • SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

Thursday, May 28, 2020 - 2:30pm

In April we launched our AT-H201 COVID-19 HOPE program for the most severely ill COVID-19 patients, commented Steven Quay, M.D., Ph.D., President and CEO of Atossa.

Key Points: 
  • In April we launched our AT-H201 COVID-19 HOPE program for the most severely ill COVID-19 patients, commented Steven Quay, M.D., Ph.D., President and CEO of Atossa.
  • By contrast, our new AT-301 nasal spray program is being developed for the relatively healthier COVID-19 patients who have not been hospitalized.
  • We are developing AT-301 with a nasal spray delivery mechanism because many COVID-19 patients are infected via the nasal passage.
  • Founded in 2009, Summit Biosciences, Inc. of Lexington, KY ( www.summitbiosciences.com ) is a privately-held, specialized pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative nasal spray medicines.

RealNetworks announces person identification on the SAFR™ ️platform for people wearing protective clothing against pandemic

Thursday, May 28, 2020 - 2:00pm

SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- RealNetworks, Inc. (NASDAQ: RNWK) - a global pioneer in video solutions, based in Seattle (USA) announces today the launch for the EMEA market of a high-performance authentication on the SAFR platform that allows identification of individuals wearing protective clothing against the pandemic.

Key Points: 
  • SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- RealNetworks, Inc. (NASDAQ: RNWK) - a global pioneer in video solutions, based in Seattle (USA) announces today the launch for the EMEA market of a high-performance authentication on the SAFR platform that allows identification of individuals wearing protective clothing against the pandemic.
  • RealNetworks informs that there will be no additional license fees for using this functionality.
  • SAFR works perfectly well with the T26 doorstation from Mobotix and the setup was straight forward due to the versatile integration capabilities of SAFR.
  • Also, according to the Larrucea, other countries like Japan and Brazil are already using the SAFR platform with authentication cases like secure and contactless access.

RealNetworks announces person identification on the SAFR™ ️platform for people wearing protective clothing against pandemic

Thursday, May 28, 2020 - 2:00pm

SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- RealNetworks, Inc. (NASDAQ: RNWK) - a global pioneer in video solutions, based in Seattle (USA) announces today the launch for the EMEA market of a high-performance authentication on the SAFR platform that allows identification of individuals wearing protective clothing against the pandemic.

Key Points: 
  • SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- RealNetworks, Inc. (NASDAQ: RNWK) - a global pioneer in video solutions, based in Seattle (USA) announces today the launch for the EMEA market of a high-performance authentication on the SAFR platform that allows identification of individuals wearing protective clothing against the pandemic.
  • RealNetworks informs that there will be no additional license fees for using this functionality.
  • SAFR works perfectly well with the T26 doorstation from Mobotix and the setup was straight forward due to the versatile integration capabilities of SAFR.
  • Also, according to the Larrucea, other countries like Japan and Brazil are already using the SAFR platform with authentication cases like secure and contactless access.

2nd Watch Joins the Google Cloud Partner Advantage Program

Thursday, May 28, 2020 - 2:00pm

SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- 2nd Watch , a leading professional services and managed cloud company, has joined the Google Cloud Partner Advantage Program, giving Google Cloud customers access to a wide range of 2nd Watch services and cloud experts.

Key Points: 
  • SEATTLE, May 28, 2020 (GLOBE NEWSWIRE) -- 2nd Watch , a leading professional services and managed cloud company, has joined the Google Cloud Partner Advantage Program, giving Google Cloud customers access to a wide range of 2nd Watch services and cloud experts.
  • As part of the Google Cloud Partner Advantage Program, 2nd Watch will guide clients Google Cloud migration efforts as well as their optimization, DevOps, analytics, and innovative architecture projects.
  • By joining the Google Cloud Partner Advantage Program, we enable our clients multi-cloud strategies, offering cloud infrastructure for specific workloads and providing the exemplary experience our clients have come to expect, said Rich Lyons, Director of Field Alliances at 2nd Watch.
  • 2nd Watch is an AWS Partner Network Premier Consulting Partner, a Microsoft Azure Gold Partner, and a Google Cloud Partner, providing professional and managed cloud services to enterprise clients.

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

Wednesday, May 27, 2020 - 9:03pm

SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will participate in the following investor virtual conferences.

Key Points: 
  • SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will participate in the following investor virtual conferences.
  • Adaptive Biotechnologiesis a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
  • We believe the adaptive immune system is natures most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.
  • Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery.

Hurricane Electric Expands High-Speed Connectivity to H5 Data Centers’ Denver Campus

Wednesday, May 27, 2020 - 2:00pm

Hurricane Electric , the worlds largest IPv6-native Internet backbone, announced today that it has added a new Point of Presence (PoP) at H5 Data Centers purpose-built campus in the Denver Tech Center.

Key Points: 
  • Hurricane Electric , the worlds largest IPv6-native Internet backbone, announced today that it has added a new Point of Presence (PoP) at H5 Data Centers purpose-built campus in the Denver Tech Center.
  • This is Hurricane Electric's 6th PoP with H5 Data Centers nationally, adding to locations in Albuquerque, Atlanta, Cleveland, San Antonio, and Seattle.
  • "Were excited to expand our relationship with H5 Data Centers, and we look forward to offering Denver enterprises and content companies additional cost-effective connectivity options, said Mike Leber, President of Hurricane Electric.
  • H5 Data Centers operates data centers in Albuquerque, Ashburn, Atlanta, Charlotte, Cincinnati, Cleveland, Denver, Phoenix, Quincy, San Antonio, San Jose, San Luis Obispo, and Seattle.

KitoTech Medical Named One of 50 Leading Companies of 2020 by The Silicon Review

Friday, May 22, 2020 - 12:00pm

SEATTLE, May 22, 2020 /PRNewswire-PRWeb/ --KitoTech Medical has been named one of the 50 Leading Companies of 2020 by the major publication The Silicon Review.

Key Points: 
  • SEATTLE, May 22, 2020 /PRNewswire-PRWeb/ --KitoTech Medical has been named one of the 50 Leading Companies of 2020 by the major publication The Silicon Review.
  • KitoTech's selection was based on an evaluation of companies in a broad range of sectors, including healthcare, information technology, clean energy, and others.
  • KitoTech received the honor for the development and commercialization of microMend, its wound closure product that is an attractive alternative to sutures.
  • More information about microMend and KitoTech Medical can be found online at http://www.kitotechmedical.com .

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

Wednesday, May 20, 2020 - 2:30pm

The preliminary study results show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which are the standard cell types being used to study infectivity of the coronavirus.

Key Points: 
  • The preliminary study results show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which are the standard cell types being used to study infectivity of the coronavirus.
  • Significant findings from the testing include:
    AT-H201 components inhibited SARS-CoV-2 from infecting VERO cells in a laboratory culture.
  • Potency was measured by microscopic examination of the cytopathic effect caused by SARS-CoV-2 in VERO cells.
  • Successful in vitro tests do not guarantee similar results from in vivo studies, including in human clinical trials.